Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma
Quanwei Zhou, Xuejun Yan, Hecheng Zhu, Zhaoqi Xin, Jin Zhao, Wenyue Shen, Wen Yin, Youwei Guo, Hongjuan Xu, Ming Zhao, Weidong Liu, Xingjun Jiang, Caiping Ren
Abstract
KDR, COL1A2, and SAMD9 are potential antigens for developing mRNA vaccines against diffuse glioma. The results suggest that immunotherapy targeting these three antigens is more suitable for patients with subtype Ims1. This study provides insights into immunotherapy for diffuse glioma.
Topics & Concepts
GliomaImmune systemAntigenImmunotherapyBiologyGeneImmunologyCancer researchGeneticsFerroptosis and cancer prognosisImmunotherapy and Immune ResponsesMicroRNA in disease regulation